1. Prosensa Patient Webinar

    Posted on January 21, 20145:09 pm

    Dr. Giles Campion, Prosensa’s Chief Medical Officer (http://www.prosensa.eu/) presented an overview of the latest drisapersen results in this morning’s patient webinar. An analysis of the Phase III data suggests that administering the drug earlier in the disease and treating longer can delay the progression of DMD. For example, in the 96-week extension data from the Read more »

  2. Prosensa Webinar on Tuesday 21st of January

    Posted on January 20, 201412:35 am

    Dear all, As announced last week, Prosensa will organize a patient focused webinar on Tuesday 21st of January at 8 AM ET / 14hrs CET. Practical details required to dial in for this webinar are provided on the Prosensa website at:  http://ir.prosensa.eu/events.cfm (open additional information by clicking on it). If you have any questions that Read more »

  3. Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy

    Posted on January 16, 20146:11 pm

    Leiden,The Netherlands,Jan. 16, 2014(GLOBE NEWSWIRE) –Prosensa Holding N.V.(NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet medical need, today announced initial findings from further analyses from the aggregate data from the clinical development program of drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD). “We are encouraged by Read more »

  4. Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

    Posted on January 15, 201411:25 pm

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 15, 2014– Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 120 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results through more than two years showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable Read more »

  5. Prosensa Patient Group Communication: Prosensa Regains Rights to Drisapersen

    Posted on January 13, 20142:50 pm

    Dear Patient Group Representative, We are writing as we would like to share with you that as of January 12, 2014, Prosensa has regained the rights to drisapersen from GSK and retained the rights to the other DMD programs. Prosensa and GSK have issued a press release to announce this news, and I have attached Read more »

  6. Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)

    Posted on 1:14 pm

    LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE   NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK)   today announced that Prosensa has regained all rights from GSK to drisapersen   and will retain rights to all other programs for the treatment of Duchenne   Muscular Dystrophy (DMD). This transfer of rights represents the Read more »